Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

by on 23 de gener de 2023 with No hi ha comentaris
  • Italiano, A., Gazzah, A., Tabernero, J., Kang, Y. K., Calvo, E., Pulla, M. P., . . . Delord, J. P. (2022). Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Annals of Oncology, 33(7), S764-S765. https://doi.org/10.1016/j.annonc.2022.07.618 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *